406 results on '"Dougall, William"'
Search Results
2. Author Correction: The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation
3. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma
4. RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer
5. The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation
6. RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer
7. NMDAR antagonists suppress tumor progression by regulating tumor-associated macrophages
8. Retraction: CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
9. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)
10. RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer.
11. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
12. Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
13. Supplementary Data from CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
14. Supplementary Methods and Legends from CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
15. Data from CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
16. Supplementary Methods and References from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
17. Supplementary Figure 1 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
18. Supplementary Figure S3 from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
19. Supplementary Table S1 from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
20. Supplementary Figure 7 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
21. Data from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
22. Supplementary Figure 5 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
23. Supplementary Methods, Figure Legends 1-7 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
24. Data from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
25. Supplementary Figure 3 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
26. Supplementary Figure 4 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
27. Supplementary Figure 2 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
28. Supplementary Table and Figure Legends from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
29. Supplementary Figure 6 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
30. New Targeted Therapies for Bone Metastases
31. NMDAR antagonists suppress tumor progression by regulating tumor-associated macrophages.
32. RANK and RANK ligand expression in primary human osteosarcoma
33. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma
34. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression
35. Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts
36. RANK Ligand Is a Therapeutic Target in Multiple Myeloma
37. RANKL Inhibition Blocks Osteolytic Lesions and Reduces Skeletal Tumor Burden in Models of Non–Small-Cell Lung Cancer Bone Metastases
38. RANKL Inhibition: From Mice to Men (and Women)
39. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
40. Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method
41. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
42. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
43. Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion
44. RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase
45. RANK expression as a prognostic and predictive marker in breast cancer
46. RANK expression on breast cancer cells promotes skeletal metastasis
47. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis
48. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone
49. Heterodimerization of Epidermal Growth Factor Receptor and Wild-Type or Kinase-Deficient Neu: A Mechanism of Interreceptor Kinase Activation and Transphosphorylation
50. Ligand and p185 c-neu Density Govern Receptor Interactions and Tyrosine Kinase Activation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.